
    
      Approximately 40 subjects will be enrolled to obtain 30 evaluable subjects. All subjects will
      receive Radium Ra 223 dichloride every 4 weeks for a total of 6 doses over 24 weeks and
      concurrent Abiraterone Acetate plus Prednisone for a minimum duration of 26 weeks.

      Subjects will be evaluated 30 days after the last dose of Radium Ra 223 dichloride. All
      adverse events deemed to be study related will be followed until resolution. Including
      screening, the total duration of the study is 32 weeks.
    
  